Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Conformetrix and AstraZeneca Sign Collaborative Agreement

Published: Thursday, April 26, 2012
Last Updated: Thursday, April 26, 2012
Bookmark and Share
First collaborative deal for Conformetrix.

Conformetrix Ltd and AstraZeneca have announced that they have signed a research collaboration agreement under which Conformetrix's proprietary NMR-based technology will be applied across AstraZeneca's pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

Conformetrix's technology determines accurate three-dimensional structures - or conformations - of drug molecules in their bioactive states.

This is achieved without the need for traditional structural information regarding the protein target of each drug and provides researchers with valuable information on how development-stage compounds are likely to interact with their targets.

This new information should improve the efficiency and quality of the lead identification, lead optimization and candidate selection stages of drug discovery programmes.

Under the terms of the two-year collaboration, the technology will also be used to determine the bioactive conformations of naturally occurring ligands as templates for drug library enhancement and hit identification.

Commenting on today's news, Conformetrix's CEO, Dr Sam Williams, said, 'Conformetrix is delighted that its first collaborative deal is with AstraZeneca, a company with a strong reputation in innovative science-led R&D. We believe that this deal provides important validation of our technology, which improves the quality and efficiency of drug discovery, reducing the number of molecules needed to find a drug and enhancing the likelihood of clinical success. The Conformetrix team is looking forward to working with our new partner on this exciting programme.'

Mike Snowden, Vice President and Head of Discovery Sciences, AstraZeneca, said: "We are excited to be working with Conformetrix. We believe their technology will provide a powerful addition to our hit identification and lead optimization approaches, supporting our strategic objectives to improve the quality and choice of candidate compounds for our early pipeline."

In addition to an undisclosed upfront payment, Conformetrix will receive research funding and be eligible for milestones as certain targets are met. The discovery programme will be managed by a joint AstraZeneca-Conformetrix research team.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Miniaturizable Magnetic Resonance
Microscopic gem the key to new development in magnetic lab-on-a-chip technology.
“Golden Window” in Deep Brain Imaging Opened
The neuroscience community is saluting the creation of a “Golden Window” for deep brain imaging by researchers at The City College of New York led by biomedical engineer Lingyan Shi.
How Viruses Commandeer Human Proteins
Researchers have produced the first image of an important human protein as it binds with ribonucleic acid (RNA), a discovery that could offer clues to how some viruses, including HIV, control expression of their genetic material.
Human Dark Proteome Initiative Launched
Group to focus on advancing research on intrinsically disordered proteins to better understand catastrophic diseases.
Clearest Ever Images of Enzyme that Plays Key Roles in Aging, Cancer
UCLA-led research on telomerase could lead to new strategies for treating disease
Analyzing Protein Structures in Their Native Environment
Enhanced-sensitivity NMR could reveal new clues to how proteins fold.
Proteins with ALS, Cancer Role Do Not Assume a Regular Shape
Our cells contain proteins, essential to functions like protein creation and DNA repair but also involved in forms of ALS and cancer, that never take a characteristic shape, a new study shows.
Studying Bowel Disease With Raman Spectroscopy
inVia confocal Raman microscope used in the study of various childhood diseases.
Pittcon Announces Sanford Asher as Recipient of the 2016 SACP Award
Asher will accept this prestigious award at Pittcon 2016 in Atlanta, Georgia.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos